Системные гипертензии

Расширенный поиск

Артериальная гипертония и ишемическая болезнь сердца: поиск оптимальных подходов к лечению (по результатам исследования INVEST)

Об авторе

И. Е. Чазова
РК НПК Минздрава РФ, Москва

Список литературы

1. Pepine C.J, Abrams J, Marks R.G et al. For the TIDES Investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994; 74: 225–31.

2. Rehnqvist N, Hiemdahl A, Billing E et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.

3. Brown M, Palmer C.R, Castaigne A et al. Morbidity and mortality in patients randomized to double - blinded treatment with a long – acting calcium – channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.

4. Hansson L, Hender T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and b - blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.

5. Staessen J.A, Fagard R, Thijs L et al. Randomised double – blind comparison of placebo and active treatment for older patients with isolated systolic hypertension/Lancet 1997; 350: 757–64.

6. The ALLHAT Officers and Coordinators. Major outcomes in high – risk hypertensive patients randomized to angiotensin – converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97.

7. Pepine C.J, Handberg-Thurmond E, Marks P et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet – based randomized trial in coronary artery disease patients with hypertension. JACC 1998; 32: 1228–37.

8. Pepine C.J, Handberg E, Cooper-De Hoff R et al. A calcium antagonist vs a non – calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA 2003; 290: 2805–16.

9. The sixth report of the Joint National committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Int Med 1997; 157: 2413–46.

10. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin – converting enzyme inhibitor, ramipril, on cardiovascular events in high – risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000; 342: 145–53.

11. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double – blind, placebo – controlled, multicenter trial (the EUROPA study). Lancet 2003; 362: 1–6.

12. Schneider M, Lerch M, Papiri M et al. Metabolic neutrality of combined verapamil – trandolapril treatment in contrast to b - blocker – low – dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypert 1996; 14: 669–77.

13. The PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double – blind trial. J. Hypert. 2002; 20: 729–37.

14. Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovacular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.


Для цитирования:

Чазова И.Е. Артериальная гипертония и ишемическая болезнь сердца: поиск оптимальных подходов к лечению (по результатам исследования INVEST). Системные гипертензии. 2004;(1):30-34.

Просмотров: 34

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)